secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2026-08-11T20:10:35+00:00
Accession:  0001493152-26-037131
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara Q2 revenue up 9% to $28.1M; adjusted EBITDA $5.0M; MIMEDX acquisition pending
--------------------------------------------------------------------------------

- Q2 net revenue $28.1M (+9% YoY); gross margin 93%; adjusted EBITDA $5.0M vs $4.7M.
- Net loss from continuing ops $0.4M ($0.05/diluted share) vs net income $0.5M ($0.05/share) in Q2 2025.
- H1 2026 revenue $55.9M (+14% YoY); adjusted EBITDA $9.3M vs $7.4M.
- Cash and equivalents $15.4M; long-term debt $46.5M at June 30, 2026 vs $16.6M and $46.0M at Dec 31, 2025.
- Announced transformational acquisition by MIMEDX, expected to combine surgical portfolios; subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315226037131/0001493152-26-037131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315226037131/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer